The role of parasite persistence in pathogenesis of Chagas heart disease

Parasite Immunology

Volumn 31, Issue 11, 2009, Pages 673-685

  Gutierrez, F R S ^a   Guedes, P M M ^a   Gazzinelli, R T ^b   Silva, J S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cytokines; Immune response; Myocarditis; Parasite persistence; Trypanosoma cruzi

Indexed keywords

CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN;

AUTOIMMUNITY; CHAGAS DISEASE; EXTRACELLULAR MATRIX; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; TRYPANOSOMA CRUZI;

ANIMALS; AUTOIMMUNITY; CHAGAS CARDIOMYOPATHY; HOST-PARASITE INTERACTIONS; HUMANS; LATIN AMERICA; TRYPANOSOMA CRUZI; VIRULENCE;

PROTOZOA; TRYPANOSOMA CRUZI;

EID: 70349967303     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01108.x     Document Type: Review

References (172)

1. WHO. Control of Chagas Disease. WHO Tech Rep Ser 2002 905 : i vi, 1 109.
2. Kirchhoff LV, Weiss LM, Wittner M Tanowitz HB. Parasitic diseases of the heart. Front Biosci 2004 9 : 706 723.
3. WHO, World Health Organization Special Programme for Research and Training in Tropical Disease Geneva, WHO, 2005 : 31 33.
4. Dias J. Epidemiologia. Rio de Janeiro, Guanabara Koogan, 2000.
5. Tafuri WL. [Pathogenesis of Chagas' disease]. Rev Inst Med Trop Sao Paulo 1987 29 : 194 199.
6. Walter A. [Human activities and American trypanosomiasis. Review of the literature]. Parasite 2003 10 : 191 204.
7. Guzman-Tapia Y, Ramirez-Sierra MJ, Escobedo-Ortegon J Dumonteil E. Effect of Hurricane Isidore on Triatoma dimidiata distribution and Chagas disease transmission risk in the Yucatan Peninsula of Mexico. Am J Trop Med Hyg 2005 73 : 1019 1025.
8. Yamagata Y Nakagawa J. Control of Chagas disease. Adv Parasitol 2006 61 : 129 165.
9. Dias JC Schofield CJ. The control of the transmission by transfusion of Chagas' disease in the Southern Cone Initiative. Rev Soc Bras Med Trop 1998 31 : 373 383.
10. Dias JC, Prata A Correia D. Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev Soc Bras Med Trop 2008 41 : 193 196.
11. Tarleton RL, Reithinger R, Urbina JA, Kitron U Gurtler RE. The challenges of Chagas disease - grim outlook or glimmer of hope. PLoS Med 2007 4 : e332.
12. Urbina JA Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003 19 : 495 501.
13. Guhl F, Restrepo M, Angulo VM, Antunes CM, Campbell-Lendrum D Davies CR. Lessons from a national survey of Chagas disease transmission risk in Colombia. Trends Parasitol 2005 21 : 259 262.
14. Ferreira H. [Acute form of Chagas' disease treated by nitrofurazone]. Rev Inst Med Trop Sao Paulo 1961 3 : 287 289.
15. Garcia S, Ramos CO, Senra JF, et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005 49 : 1521 1528.
16. Reyes PA Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005 CD004102.
17. Villar JC, Marin-Neto JA, Ebrahim S Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002 CD003463.
18. Marin-Neto JA, Rassi A Jr., Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008 156 : 37 43.
19. Schijman AG, Vigliano CA, Viotti RJ, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart disease. Am J Trop Med Hyg 2004 70 : 210 220.
20. Brener Z. Biology of Trypanosoma cruzi. Annu Rev Microbiol 1973 27 : 347 382.
21. Chagas C. Nova tripanozomiaze humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n.gen., n.sp., ajente etiolojico de nova entidade morbida do homem - Ueber eine neue Trypanosomiasis des Menschen. Studien über Morphologie und Entwicklungszyklus des Schizotrypanum cruzi n. gen., n. sp., Erreger einer neuen Krankheit des Menschen. Mem Inst Oswaldo Cruz 1909 159 218.
22. Mazza S. Nota sobre el primer centenar de formas agudas de la enfermedad de Chagas comprobadas en la República por la Misión de Estudios de Patología Regional Argentina. Prensa Medica Argentina 1936 1979 1981.
23. Dias E Pellegrino J. Alguns ensaios com o gammexane no combate aos transmissores da doença de Chagas. Brasil Médico 1948 185 191.
24. Morel CM. Chagas disease, from discovery to control - and beyond: history, myths and lessons to take home. Mem Inst Oswaldo Cruz 1999 94 (Suppl 1 3 16.
25. Savino W. The thymus is a common target organ in infectious diseases. PLoS Pathol 2006 2 : e62.
26. Laucella S, Salcedo R, Castanos-Velez E, et al. Increased expression and secretion of ICAM-1 during experimental infection with Trypanosoma cruzi. Parasite Immunol 1996 18 : 227 239.
27. Lannes-Vieira J. Trypanosoma cruzi-elicited CD8+ T cell-mediated myocarditis: chemokine receptors and adhesion molecules as potential therapeutic targets to control chronic inflammation? Mem Inst Oswaldo Cruz 2003 98 : 299 304.
28. Tsuruda T, Costello-Boerrigter LC Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 2004 9 : 53 61.
29. Gutierrez FR, Lalu MM, Mariano FS, et al. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. J Infect Dis 2008 197 : 1468 1476.
30. Rottenberg M, Cardoni RL, Andersson R, Segura EL Orn A. Role of T helper/inducer cells as well as natural killer cells in resistance to Trypanosoma cruzi infection. Scand J Immunol 1988 28 : 573 582.
31. Tarleton RL. The role of T cells in Trypanosoma cruzi infections. Parasitol Today 1995 11 : 7 9.
32. Bixby LM Tarleton RL. Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol 2008 181 : 2644 2650.
33. Nickell SP, Gebremichael A, Hoff R Boyer MH. Isolation and functional characterization of murine T cell lines and clones specific for the protozoan parasite Trypanosoma cruzi. J Immunol 1987 138 : 914 921.
34. Martins GA, Campanelli AP, Silva RB, et al. CD28 is required for T cell activation and IFN-gamma production by CD4+ and CD8+ T cells in response to Trypanosoma cruzi infection. Microbes Infect 2004 6 : 1133 1144.
35. Krettli AU Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol 1976 116 : 755 760.
36. Aliberti JC, Souto JT, Marino AP, et al. Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol 2001 158 : 1433 1440.
37. Holscher C, Kohler G, Muller U, Mossmann H, Schaub GA Brombacher F. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 1998 66 : 1208 1215.
38. Castanos-Velez E, Maerlan S, Osorio LM, et al. Trypanosoma cruzi infection in tumor necrosis factor receptor p55-deficient mice. Infect Immun 1998 66 : 2960 2968.
39. Silva JS, Vespa GN, Cardoso MA, Aliberti JC Cunha FQ. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 1995 63 : 4862 4867.
40. Vespa GN, Cunha FQ Silva JS. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 1994 62 : 5177 5182.
41. Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ Silva JS. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 1996 64 : 1961 1967.
42. Gazzinelli RT, Oswald IP, Hieny S, James SL Sher A. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur J Immunol 1992 22 : 2501 2506.
43. Moncada S Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 1991 21 : 361 374.
44. Cardillo F, Voltarelli JC, Reed SG Silva JS. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun 1996 64 : 128 134.
45. Reed SG. Immunology of Trypanosoma cruzi infections. Chem Immunol 1998 70 : 124 143.
46. Torrico F, Heremans H, Rivera MT, Van Marck E, Billiau A Carlier Y. Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol 1991 146 : 3626 3632.
47. Silva JS, Twardzik DR Reed SG. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med 1991 174 : 539 545.
48. Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D Reed SG. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med 1992 175 : 169 174.
49. Dutra WO, Martins-Filho OA, Cancado JR, et al. Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Int Immunol 1994 6 : 499 506.
50. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun 2003 71 : 1185 1193.
51. Silva JS, Machado FS Martins GA. The role of nitric oxide in the pathogenesis of Chagas disease. Front Biosci 2003 8 : s314 325.
52. Gazzinelli RT, Wysocka M, Hieny S, et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 1996 157 : 798 805.
53. Gomes JA, Bahia-Oliveira LM, Rocha MO, et al. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. Infect Immun 2005 73 : 7960 7966.
54. Teixeira MM, Gazzinelli RT Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 2002 18 : 262 265.
55. Machado FS, Koyama NS, Carregaro V, et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 2005 191 : 627 636.
56. Machado FS, Martins GA, Aliberti JC, Mestriner FL, Cunha FQ Silva JS. Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation 2000 102 : 3003 3008.
57. Dutra WO, da Luz ZM, Cancado JR, et al. Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy. Parasite Immunol 1996 18 : 579 585.
58. Melo RC Brener Z. Tissue tropism of different Trypanosoma cruzi strains. J Parasitol 1978 64 : 475 482.
59. Minoprio P, Burlen O, Pereira P, et al. Most B cells in acute Trypanosoma cruzi infection lack parasite specificity. Scand J Immunol 1988 28 : 553 561.
60. Higuchi Mde L, Gutierrez PS, Aiello VD, et al. Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Pathol Anat Histopathol 1993 423 : 157 160.
61. Higuchi MD, Ries MM, Aiello VD, et al. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 1997 56 : 485 489.
62. Reis MM, Higuchi Mde L, Benvenuti LA, et al. An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in chronic human chagasic myocarditis: correlation with the presence of myocardial Trypanosoma cruzi antigens. Clin Immunol Immunopathol 1997 83 : 165 172.
63. Tarleton RL. Depletion of CD8+ T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J Immunol 1990 144 : 717 724.
64. Caulada-Benedetti Z, Vecchio LC, Pardi CC, Massironi SM, D'Imperio Lima MR Abrahamsohn IA. Activation of CD4+ and CD8+ parasite -specific T-cells by macrophages infected with live T. cruzi amastigotes. Immunol Lett 1998 63 : 97 105.
65. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007 7 : 875 888.
66. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007 450 : 566 569.
67. Zheng SG, Wang JH, Gray JD, Soucier H Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004 172 : 5213 5221.
68. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. The Journal of experimental medicine 1986 163 : 1037 1050.
69. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 1988 140 : 3026 3032.
70. Kehrl JH, Grove JH, Goldsmith PK Fauci AS. B cell growth and differentiation factors interact with receptors distinct from the interleukin 2 receptor. Eur J Immunol 1986 16 : 761 766.
71. Czarniecki CW, Chiu HH, Wong GH, McCabe SM Palladino MA. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988 140 : 4217 4223.
72. Mule JJ, Schwarz SL, Roberts AB, Sporn MB Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988 26 : 95 100.
73. Kotner J Tarleton R. Endogenous CD4(+) CD25(+) regulatory T cells have a limited role in the control of Trypanosoma cruzi infection in mice. Infect Immun 2007 75 : 861 869.
74. Mariano FS, Gutierrez FR, Pavanelli WR, et al. The involvement of CD4(+)CD25(+) T cells in the acute phase of Trypanosoma cruzi infection. Microbes Infect 2008 10 : 825 833.
75. Sales PA Jr., Golgher D, Oliveira RV, et al. The regulatory CD4+CD25+ T cells have a limited role on pathogenesis of infection with Trypanosoma cruzi. Microbes Infect 2008 10 : 680 688.
76. Mariano FS, Gutierrez FR, Pavanelli WR, et al. The involvement of CD4+CD25+ T cells in the acute phase of Trypanosoma cruzi infection. Microbes Infect 2008 10 : 825 833.
77. Araujo-Jorge TC, Waghabi MC, Soeiro MD, Keramidas M, Bailly S Feige JJ. Pivotal role for TGF-beta in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine Growth Factor Rev 2008 19 : 405 413.
78. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005 6 : 1133 1141.
79. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008 8 : 337 348.
80. Singh SP, Zhang HH, Foley JF, Hedrick MN Farber JM. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008 180 : 214 221.
81. Nakae S, Saijo S, Horai R, Sudo K, Mori S Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003 100 : 5986 5990.
82. Kolls JK Linden A. Interleukin-17 family members and inflammation. Immunity 2004 21 : 467 476.
83. Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007 37 : 2695 2706.
84. Tesmer LA, Lundy SK, Sarkar S Fox DA. Th17 cells in human disease. Immunol Rev 2008 223 : 87 113.
85. Rutitzky LI Stadecker MJ. CD4 T cells producing pro-inflammatory interleukin-17 mediate high pathology in schistosomiasis. Mem Inst Oswaldo Cruz 2006 101 (Suppl 1 327 330.
86. Matsuzaki G Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007 51 : 1139 1147.
87. Weaver CT, Hatton RD, Mangan PR Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007 25 : 821 852.
88. Sallusto F Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000 177 : 134 140.
89. Gerard C Rollins BJ. Chemokines and disease. Nat Immunol 2001 2 : 108 115.
90. Moser B Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001 2 : 123 128.
91. Villalta F, Zhang Y, Bibb KE, Kappes JC Lima MF. The cysteine-cysteine family of chemokines RANTES, MIP-1alpha, and MIP-1beta induce trypanocidal activity in human macrophages via nitric oxide. Infect Immun 1998 66 : 4690 4695.
92. Aliberti JC, Machado FS, Souto JT, et al. beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun 1999 67 : 4819 4826.
93. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998 101 : 746 754.
94. Chamond N, Coatnoan N Minoprio P. Immunotherapy of Trypanosoma cruzi infections. Curr Drug Targets Immune Endocr Metabol Disord 2002 2 : 247 254.
95. Zhang L Tarleton RL. Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production. Eur J Immunol 1996 26 : 102 109.
96. Reis DD, Gazzinelli RT, Gazzinelli G Colley DG. Antibodies to Trypanosoma cruzi express idiotypic patterns that can differentiate between patients with asymptomatic or severe Chagas' disease. J Immunol 1993 150 : 1611 1618.
97. Abel LC, Rizzo LV, Ianni B, et al. Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. J Autoimmun 2001 17 : 99 107.
98. Bahia-Oliveira LM, Gomes JA, Rocha MO, et al. IFN-gamma in human Chagas' disease: protection or pathology? Braz J Med Biol Res 1998 31 : 127 131.
99. Correa-Oliveira R, Gomes J, Lemos EM, et al. The role of the immune response on the development of severe clinical forms of human Chagas disease. Mem Inst Oswaldo Cruz 1999 94 (Suppl 1 253 255.
100. Ribeirao M, Pereira-Chioccola VL, Renia L, Augusto Fragata Filho A, Schenkman S Rodrigues MM. Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase. Parasite Immunol 2000 22 : 49 53.
101. Dutra WO, Gollob KJ, Pinto-Dias JC, et al. Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Scand J Immunol 1997 45 : 74 80.
102. Guedes PM, Veloso VM, Gollob KJ, et al. IgG isotype profile is correlated with cardiomegaly in Beagle dogs infected with distinct Trypanosoma cruzi strains. Vet Immunol Immunopathol 2008 124 : 163 168.
103. Minoprio PM, Eisen H, Forni L, D'Imperio Lima MR, Joskowicz M Coutinho A. Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. I. Quantitation of both T- and B-cell responses. Scand J Immunol 1986 24 : 661 668. (Pubitemid 17212845)
104. Valente SA, da Costa Valente V, das Neves Pinto AY, et al. Analysis of an acute Chagas disease outbreak in the Brazilian Amazon: human cases, triatomines, reservoir mammals and parasites. Trans R Soc Trop Med Hyg 2009 103 : 291 297.
105. Girones N, Rodriguez CI, Basso B, et al. Antibodies to an epitope from the Cha human autoantigen are markers of Chagas' disease. Clin Diagn Lab Immunol 2001 8 : 1039 1043.
106. Lopez Bergami P, Scaglione J Levin MJ. Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic. FASEB J 2001 15 : 2602 2612.
107. Levin MJ, Mesri E, Benarous R, et al. Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas' heart disease. Am J Trop Med Hyg 1989 41 : 530 538.
108. Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N Kalil J. Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient. J Clin Invest 1996 98 : 1709 1712.
109. Kerner N, Liegeard P, Levin MJ Hontebeyrie-Joskowicz M. Trypanosoma cruzi: antibodies to a MAP-like protein in chronic Chagas' disease cross-react with mammalian cytoskeleton. Exp Parasitol 1991 73 : 451 459.
110. Levin MJ Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity 2008 41 : 429 433.
111. Kierszenbaum F Howard JG. Mechanisms of resistance against experimental Trypanosoma cruzi infection: the importance of antibodies and antibody-forming capacity in the Biozzi high and low responder mice. J Immunol 1976 116 : 1208 1211.
112. Almeida IC, Milani SR, Gorin PA Travassos LR. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J Immunol 1991 146 : 2394 2400.
113. Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA Romanha AJ. Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob Agents Chemother 2009 53 : 174 179.
114. Watthanakulpanich D, Smith HV, Hobbs G, Whalley AJ Billington D. Application of Toxocara canis excretory-secretory antigens and IgG subclass antibodies (IgG1-4) in serodiagnostic assays of human toxocariasis. Acta Trop 2008 106 : 90 95.
115. Kawano Y, Noma T Yata J. Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol 1994 153 : 4948 4958.
116. Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 1994 179 : 757 762.
117. Fanger MW, Segal DM Romet-Lemonne JL. Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today 1991 12 : 51 54.
118. Michailowsky V, Luhrs K, Rocha MO, Fouts D, Gazzinelli RT Manning JE. Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease. Infect Immun 2003 71 : 3165 3171.
119. Morgan J, Dias JC, Gontijo ED, et al. Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease. Am J Trop Med Hyg 1996 55 : 355 359.
120. Cerban FM, Gea S, Menso E Vottero-Cima E. Chagas' disease: IgG isotypes against Trypanosoma cruzi cytosol acidic antigens in patients with different degrees of heart damage. Clin Immunol Immunopathol 1993 67 : 25 30.
121. Giordanengo L, Maldonado C, Rivarola HW, et al. Induction of antibodies reactive to cardiac myosin and development of heart alterations in cruzipain-immunized mice and their offspring. European journal of immunology 2000 30 : 3181 3189.
122. Cordeiro FD, Martins-Filho OA, Da Costa Rocha MO, Adad SJ, Correa-Oliveira R Romanha AJ. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol 2001 8 : 112 118.
123. Singer GG, Carrera AC, Marshak-Rothstein A, Martinez C Abbas AK. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol 1994 6 : 913 920.
124. Estaquier J Ameisen JC. A role for T-helper type-1 and type-2 cytokines in the regulation of human monocyte apoptosis. Blood 1997 90 : 1618 1625.
125. Dimmeler S Zeiher AM. Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. Nitric Oxide 1997 1 : 275 281.
126. Martins GA, Vieira LQ, Cunha FQ Silva JS. Gamma interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control. Infect Immun 1999 67 : 3864 3871.
127. Fukuo K, Hata S, Suhara T, et al. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 1996 27 : 823 826.
128. Ferrero-Garcia MA, Trombetta SE, Sanchez DO, Reglero A, Frasch AC Parodi AJ. The action of Trypanosoma cruzi trans-sialidase on glycolipids and glycoproteins. Eur J Biochem 1993 213 : 765 771.
129. Buscaglia CA, Alfonso J, Campetella O Frasch AC. Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood. Blood 1999 93 : 2025 2032.
130. Alvarez MN, Piacenza L, Irigoin F, Peluffo G Radi R. Macrophage-derived peroxynitrite diffusion and toxicity to Trypanosoma cruzi. Arch Biochem Biophys 2004 432 : 222 232.
131. Risso MG, Garbarino GB, Mocetti E, et al. Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J Infect Dis 2004 189 : 2250 2259.
132. Leguizamon MS, Mocetti E, Garcia Rivello H, Argibay P Campetella O. Trans-sialidase from Trypanosoma cruzi induces apoptosis in cells from the immune system in vivo. J Infect Dis 1999 180 : 1398 1402.
133. Mucci J, Hidalgo A, Mocetti E, Argibay PF, Leguizamon MS Campetella O. Thymocyte depletion in Trypanosoma cruzi infection is mediated by trans-sialidase-induced apoptosis on nurse cells complex. Proc Natl Acad Sci U S A 2002 99 : 3896 3901.
134. Mucci J, Risso MG, Leguizamon MS, Frasch AC Campetella O. The trans-sialidase from Trypanosoma cruzi triggers apoptosis by target cell sialylation. Cell Microbiol 2006 8 : 1086 1095.
135. Gao W, Wortis HH Pereira MA. The Trypanosoma cruzi trans-sialidase is a T cell-independent B cell mitogen and an inducer of non-specific Ig secretion. Int Immunol 2002 14 : 299 308.
136. Krettli AU, Weisz-Carrington P Nussenzweig RS. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol 1979 37 : 416 423.
137. Kipnis TL, Krettli AU Dias da Silva W. Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol 1985 22 : 217 226.
138. Martins MS, Hudson L, Krettli AU, Cancado JR Brener Z. Human and mouse sera recognize the same polypeptide associated with immunological resistance to Trypanosoma cruzi infection. Clin Exp Immunol 1985 61 : 343 350.
139. Norris KA, Bradt B, Cooper NR So M. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J Immunol 1991 147 : 2240 2247.
140. Norris KA. Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance. Infect Immun 1998 66 : 2460 2465.
141. Aguilar L, Ramirez G, Valck C, et al. F(ab')2 antibody fragments against Trypanosoma cruzi calreticulin inhibit its interaction with the first component of human complement. Biol Res 2005 38 : 187 195.
142. McConville MJ Schneider P. Conservation of surface molecules in the trypanosomatids. Parasitol Today 1993 9 : 316 317.
143. de Diego J, Punzon C, Duarte M Fresno M. Alteration of macrophage function by a Trypanosoma cruzi membrane mucin. J Immunol 1997 159 : 4983 4989.
144. Oliveira AC, Peixoto JR, de Arruda LB, et al. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol 2004 173 : 5688 5696.
145. Takeda K, Kaisho T Akira S. Toll-like receptors. Annu Rev Immunol 2003 21 : 335 376.
146. Ropert C Gazzinelli RT. Regulatory role of Toll-like receptor 2 during infection with Trypanosoma cruzi. J Endotoxin Res 2004 10 : 425 430.
147. Carrera-Silva EA, Carolina CR, Natalia G, Pilar AM, Andrea P Gea S. TLR2, TLR4 and TLR9 are differentially modulated in liver lethally injured from BALB/c and C57BL/6 mice during Trypanosoma cruzi acute infection. Mol Immunol 2008 45 : 3580 3588.
148. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003 362 : 1469 1480.
149. Guhl F, Jaramillo C, Yockteng R, Vallejo GA Cardenas-Arroyo F. Trypanosoma cruzi DNA in human mummies. Lancet 1997 349 : 1370.
150. Higuchi ML, De Morais CF, Pereira Barreto AC, et al. The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies. Clin Cardiol 1987 10 : 665 670.
151. Tarleton RL Zhang L. Chagas disease etiology: autoimmunity or parasite persistence? Parasitol Today 1999 15 : 94 99.
152. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001 31 : 550 554.
153. Acosta AM Santos-Buch CA. Autoimmune myocarditis induced by Trypanosoma cruzi. Circulation 1985 71 : 1255 1261.
154. Rizzo LV, Cunha-Neto E Teixeira AR. Autoimmunity in Chagas' disease: immunomodulation of autoimmune and T. cruzi-specific immune responses. Mem Inst Oswaldo Cruz 1988 83 (Suppl 1 360 362.
155. Leon JS, Daniels MD, Toriello KM, Wang K Engman DM. A cardiac myosin-specific autoimmune response is induced by immunization with Trypanosoma cruzi proteins. Infect Immun 2004 72 : 3410 3417.
156. Levin MJ, Kaplan D, Ferrari I, Arteman P, Vazquez M Panebra A. Humoral autoimmune response in Chagas' disease: Trypanosoma cruzi ribosomal antigens as immunizing agents. FEMS Immunol Med Microbiol 1993 7 : 205 210.
157. Cunha-Neto E, Duranti M, Gruber A, et al. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci USA 1995 92 : 3541 3545.
158. Cunha-Neto E Kalil J. Heart-infiltrating and peripheral T cells in the pathogenesis of human Chagas' disease cardiomyopathy. Autoimmunity 2001 34 : 187 192.
159. Leon JS, Wang K Engman DM. Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas' disease. J Immunol 2003 171 : 4271 4277.
160. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 1993 48 : 348 357.
161. Anez N, Carrasco H, Parada H, et al. Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 1999 60 : 726 732.
162. Lages-Silva E, Crema E, Ramirez LE, Macedo AM, Pena SD Chiari E. Relationship between Trypanosoma cruzi and human chagasic megaesophagus: blood and tissue parasitism. Am J Trop Med Hyg 2001 65 : 435 441.
163. Vago AR, Macedo AM, Oliveira RP, et al. Kinetoplast DNA signatures of Trypanosoma cruzi strains obtained directly from infected tissues. Am J Pathol 1996 149 : 2153 2159.
164. Higuchi ML. Chagas disease. Importance of the parasite in the pathogenesis of the cardiac chronic disease. Arq Bras Cardiol 1995 64 : 251 254.
165. De Araujo SM Chiari E. Biological characterization of clones of the Y, CL and MR strains of Trypanosoma cruzi in inbred C3H mice. Mem Inst Oswaldo Cruz 1988 83 : 175 181.
166. Macedo AM, Machado CR, Oliveira RP Pena SD. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of chagas disease. Mem Inst Oswaldo Cruz 2004 99 : 1 12.
167. Guedes PM, Veloso VM, Caliari MV, et al. Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in Beagle dogs. Mem Inst Oswaldo Cruz 2007 102 : 141 147.
168. Bellotti G, Bocchi EA, de Moraes AV, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am Heart J 1996 131 : 301 307.
169. Rossi MA. Connective tissue skeleton in the normal left ventricle and in hypertensive left ventricular hypertrophy and chronic chagasic myocarditis. Med Sci Monit 2001 7 : 820 832.
170. Dutra WO, Rocha MO Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasitol 2005 21 : 581 587.
171. Oria J Ramos J. Alterações do metassimpático do coração nos portadores de megaesôfago. Arq Bras Cardiol 1949 311 316.
172. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002 90 : 520 530.